Vatsal Meditech(@VatsalMeditech) 's Twitter Profile Photo

# Imatirel 400mg tablet

Imatirel 400mg tablet 10's contains the active substance imatinib. It is an antineoplastic drug that belongs to the class tyrosine kinase inhibitor. This tablet is used treating adults and children with chronic myeloid leukemia

# Imatirel 400mg tablet 

Imatirel 400mg tablet 10's contains the active substance imatinib. It is an antineoplastic drug that belongs to the class tyrosine kinase inhibitor. This tablet is used treating adults and children with chronic myeloid leukemia
account_circle
Vatsal Meditech(@VatsalMeditech) 's Twitter Profile Photo

# Imatinib mesylate

Imatinib mesylate is used in the treatment of blood cancer (chronic myeloid leukaemia), blood cancer (acute lymphocytic leukemia) and gastrointestinal stromal tumour.
How Imatinib mesylate works
Imatinib mesylate is an anti-cancer medication. A protein enzyme

# Imatinib mesylate

Imatinib mesylate is used in the treatment of blood cancer (chronic myeloid leukaemia), blood cancer (acute lymphocytic leukemia) and gastrointestinal stromal tumour.
How Imatinib mesylate works
Imatinib mesylate is an anti-cancer medication. A protein enzyme
account_circle
Mangel ⚔️(@Mangelgalo_19) 's Twitter Profile Photo

Acabo de descubrir que el nombre de los anticuerpos monoclonales acaban en -ab (trastuzumAB, cetuximAB) porque son AntiBodies y los que acaban en -inib (imatINIB) son Inhibidores de alguna Tirosin Kinasa

Ahora tienen un poquito más de sentido los nombres

account_circle
Roberto Pestana, MD(@PestanaRC) 's Twitter Profile Photo

In parallel, trials were developed to answer the question of extending treatment.

PERSIST-5 is a phase II trial of adjuvant imatinib for 5 yeaers, by Jon Trent, MD, PhD and colleagues

Raut CP. JAMA Oncol 4:1e184060, 2018.

In parallel,  trials were developed to answer the question of extending treatment. 

PERSIST-5 is a phase II trial of adjuvant imatinib for 5 yeaers, by @JTrentMDPhD  and colleagues

Raut CP. JAMA Oncol 4:1e184060, 2018.
account_circle
Roberto Pestana, MD(@PestanaRC) 's Twitter Profile Photo

And now we have the firs randomized data to come out, regarding the IMADGIST trial.

This is a multicenter open-label, randomized, phase III study evaluating maintenance of imatinib at the last dose routinely taken by the patient in the 3-year period prior to randomization…

And now we have the firs randomized data to come out, regarding the IMADGIST trial. 

This is a multicenter open-label, randomized, phase III study evaluating maintenance of imatinib at the last dose routinely taken by the patient in the 3-year period prior to randomization…
account_circle
Roberto Pestana, MD(@PestanaRC) 's Twitter Profile Photo

The ACOZOG Z9001 enrolled patients with resected GIST at least 3 cm in size that stained positive for KIT protein. Patients were randomized to 1y of imatinib or placebo.

Imatinib significantly prolonged RFS compared with placebo (98% vs. 83% at 1 year; HR 0.35)

However, look…

The ACOZOG Z9001 enrolled patients with resected GIST  at least 3 cm in size that stained positive for KIT protein. Patients were randomized to 1y of imatinib or placebo. 

Imatinib significantly prolonged RFS compared with placebo (98% vs. 83% at 1 year; HR 0.35)

However, look…
account_circle
EurekaMag(@EurekaMag) 's Twitter Profile Photo

Treatment selection after imatinib resistance in chronic myeloid leukemia eurekamag.com/research/056/6…

Treatment selection after imatinib resistance in chronic myeloid leukemia eurekamag.com/research/056/6…
account_circle
Roberto Pestana, MD(@PestanaRC) 's Twitter Profile Photo

So....should we extend imatinib? Especially in high-risk disease?

The elegant SSG XVIII trial then randomized patients to 12 months of imatinib (the standard following ACOZOG Z9001) versus 36 months. This trial, in addition, enrolled a high risk population by NIH criteria.…

So....should we extend imatinib? Especially in high-risk disease?

The elegant SSG XVIII trial then randomized patients to 12 months of imatinib (the standard following ACOZOG Z9001) versus 36 months. This trial, in addition, enrolled a high risk population by NIH criteria.…
account_circle